71.28
price down icon0.68%   -0.49
 
loading
Arcellx Inc stock is traded at $71.28, with a volume of 454.77K. It is down -0.68% in the last 24 hours and up +4.44% over the past month. Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$71.77
Open:
$72.2
24h Volume:
454.77K
Relative Volume:
0.80
Market Cap:
$3.95B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-23.84
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
-3.78%
1M Performance:
+4.44%
6M Performance:
+11.81%
1Y Performance:
+7.25%
1-Day Range:
Value
$70.94
$73.33
1-Week Range:
Value
$69.00
$74.73
52-Week Range:
Value
$47.86
$107.37

Arcellx Inc Stock (ACLX) Company Profile

Name
Name
Arcellx Inc
Name
Phone
240-327-0603
Name
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Name
Employee
163
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ACLX's Discussions on Twitter

Compare ACLX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACLX
Arcellx Inc
71.28 3.98B 76.81M -162.42M -122.49M -2.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Arcellx Inc Stock (ACLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-25 Initiated Citigroup Buy
Oct-08-24 Initiated Redburn Atlantic Buy
Sep-03-24 Initiated Cantor Fitzgerald Overweight
May-31-24 Initiated Piper Sandler Overweight
Mar-07-24 Initiated Morgan Stanley Overweight
Jan-04-24 Reiterated Needham Buy
Dec-19-23 Initiated Scotiabank Sector Outperform
Oct-30-23 Initiated TD Cowen Outperform
Oct-17-23 Initiated UBS Buy
May-18-23 Initiated Truist Buy
Apr-14-23 Initiated Robert W. Baird Outperform
Mar-14-23 Initiated Stifel Buy
Feb-13-23 Initiated H.C. Wainwright Buy
Dec-13-22 Resumed BofA Securities Buy
Oct-31-22 Initiated Guggenheim Buy
Oct-27-22 Initiated Needham Buy
Jul-20-22 Initiated Canaccord Genuity Buy
Mar-01-22 Initiated BofA Securities Buy
Mar-01-22 Initiated SVB Leerink Outperform
View All

Arcellx Inc Stock (ACLX) Latest News

pulisher
Aug 19, 2025

Traders Watching For Reversal Pattern in Arcellx Inc.2025 Price Action Summary & Advanced Technical Signal Analysis - 선데이타임즈

Aug 19, 2025
pulisher
Aug 18, 2025

Watch for Bullish Crossover in Arcellx Inc.Options Play & AI Enhanced Market Trend Forecasts - beatles.ru

Aug 18, 2025
pulisher
Aug 18, 2025

Tick level data insight on Arcellx Inc. volatilityWeekly Gains Report & Capital Efficient Trade Techniques - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Has Arcellx Inc. formed a bullish divergenceJuly 2025 Trends & Safe Capital Growth Tips - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Long term hold vs stop loss in Arcellx Inc.2025 Major Catalysts & Verified High Yield Trade Plans - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

How Arcellx Inc. stock performs during market volatilityEarnings Overview Report & Expert Approved Momentum Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Pattern recognition hints at Arcellx Inc. upsideWeekly Investment Report & Verified Momentum Watchlists - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Combining price and volume data for Arcellx Inc.Market Growth Review & Pattern Based Trade Signal System - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Do Higher Losses at Arcellx (ACLX) Reflect a Strategic Shift or Growing Pains? - simplywall.st

Aug 17, 2025
pulisher
Aug 17, 2025

Financial Analysis: Arcellx (NASDAQ:ACLX) and Astria Therapeutics (NASDAQ:ATXS) - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Arcellx, Inc. (NASDAQ:ACLX) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Backtesting results for Arcellx Inc. trading strategies2025 Buyback Activity & Expert Curated Trade Setup Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Real time scanner hits for Arcellx Inc. explainedQuarterly Risk Review & Daily Price Action Insights - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Will Arcellx Inc. stock go up soon2025 Fundamental Recap & Technical Buy Zone Confirmations - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Is Arcellx Inc. stock a buy or sellPortfolio Profit Report & Stepwise Trade Signal Guides - thegnnews.com

Aug 16, 2025
pulisher
Aug 16, 2025

Heatmap analysis for Arcellx Inc. and competitorsMarket Activity Recap & Free Weekly Chart Analysis and Trade Guides - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Is Arcellx Inc. a candidate for recovery play2025 Risk Factors & Weekly Watchlist for Consistent Profits - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Historical volatility pattern of Arcellx Inc. visualized2025 Earnings Impact & Free Technical Pattern Based Buy Signals - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Is Now a Good Time to Reenter Arcellx Inc.Risk Management & Low Risk Investment Opportunities - 선데이타임즈

Aug 14, 2025
pulisher
Aug 14, 2025

Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs - MSN

Aug 14, 2025
pulisher
Aug 13, 2025

Widening Losses in Q2 and H1 Might Change the Case for Investing in Arcellx (ACLX) - simplywall.st

Aug 13, 2025
pulisher
Aug 12, 2025

Applying big data sentiment scoring on Arcellx Inc.Free Daily Picks With Predictable Performance - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Smart tools for monitoring Arcellx Inc.’s price actionFree Chart Driven High Reward Trading Setup - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Is this a good reentry point in Arcellx Inc.Future Growth Stock Forecasting Strategy - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Evercore Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛

Aug 12, 2025
pulisher
Aug 12, 2025

Evercore ISI Maintains Buy Rating on Arcellx Inc with $115 Price Target - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Why Arcellx Inc. stock attracts strong analyst attentionDaily Upside Movement Prediction With Data - Newser

Aug 12, 2025
pulisher
Aug 11, 2025

Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail

Aug 11, 2025
pulisher
Aug 10, 2025

Can you recover from losses in Arcellx Inc.Free Risk Managed Intraday Trade Alerts - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

We Think Arcellx (NASDAQ:ACLX) Can Afford To Drive Business Growth - Yahoo Finance

Aug 10, 2025
pulisher
Aug 09, 2025

A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $134 - 富途牛牛

Aug 09, 2025
pulisher
Aug 09, 2025

Canaccord Genuity Sticks to Its Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail

Aug 09, 2025
pulisher
Aug 09, 2025

Using Ichimoku Cloud for Arcellx Inc. technicalsOversold Opportunity Scanner with RSI Data - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Using Bollinger Bands to evaluate Arcellx Inc.Near-Term Market Opportunity Forecast Sheet - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Published on: 2025-08-08 23:14:52 - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Arcellx Inc. stock volume spike explainedLoss Limitation Strategy Based on Analysis - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Did Widening Losses and Falling Sales Just Shift Arcellx's (ACLX) Investment Narrative? - simplywall.st

Aug 08, 2025
pulisher
Aug 08, 2025

Arcellx 2025 Q2 Earnings Deepened Losses Amid Declining Revenue - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Does Arcellx Inc. have a sustainable dividendShort-Term Explosive Growth - thegnnews.com

Aug 08, 2025
pulisher
Aug 08, 2025

Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Arcellx shares rise 3.32% intraday after reporting positive Q2 2025 financial results and potential life-changing therapy for multiple myeloma patients. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights - BioSpace

Aug 08, 2025
pulisher
Aug 08, 2025

Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

Arcellx earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Arcellx Inc Shares Dip Amid Revenue Concerns - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Arcellx reports Q2 EPS (94c), consensus ($1.03) - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Arcellx Q2 Revenue Misses Estimates, Adjusted EPS Beats Consensus - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings Flash (ACLX) Arcellx, Inc. Reports Q2 Revenue $7.6M, vs. FactSet Est of $13.5M - MarketScreener

Aug 07, 2025

Arcellx Inc Stock (ACLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Arcellx Inc Stock (ACLX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Patel Kavita
Director
Jun 10 '25
Sale
67.36
1,500
101,040
0
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):